US and UK Establish Tariff-Free Agreement on Prescription Drugs.
Britain and America have hammered out a significant trade agreement that will ensure zero tariffs on British pharmaceutical exports being sold in the US market.
Key Provisions of the Accord
As part of the deal, the UK has pledged to increase expenditure on medicines through the National Health Service (NHS). This move guarantees that import taxes on these key products will stay at nothing for a duration of three years.
This development comes after previous threats to dramatically increase duties on patented pharmaceutical products, with increases discussed reaching 100%.
"This arrangement with the Britain strengthens the global environment for new treatments and brings much-needed fairness to American-British medicine commerce," a statement noted.
Economic Importance
Drugs are one of the Britain's largest exports to the US, which is by far the primary market for large UK drugmakers.
Trade data show that in the one-year period prior to September, the UK sold pharmaceutical products totaling £11.1bn to the US. This value accounted for 17.4% of British export trade in that period.
"This guarantee secures work, boosts funding and paves the way for the UK to emerge as a global hub for medical research," a government official stated.
Specific UK Commitments
The deal includes several notable changes from the British government:
- Revised Affordability Limit: The UK will lift the affordability limit at which it judges new medicines to be too expensive by a quarter.
- Higher Drug Budget: There is a aim to raise total public funding on drugs from 0.3% of GDP to 0.6% over the next decade.
- Refund Ceiling: The amount drug companies must refund to the NHS to prevent overspending will be capped at 15%. Last year, rebates topped twenty percent.
Recent Tensions
The deal comes amid a long-running tension between the drug companies and the British authorities over spending levels and NHS adoption.
This friction were heightened by claims that American customers were paying a premium for the equivalent treatments than consumers in the UK and Europe.
In recent months, several significant manufacturing plans in the UK have been delayed or scrapped, while multi-billion-dollar expansions have been directed toward American operations.
One official stated that the NHS needed to increase expenditure on treatments, noting that its expenditure on drugs had shrunk as a share of its total funding over the past decade.